Comprehensive treatment of liver cancer

Multimodal comprehensive treatment of liver cancer is an effective treatment for large mid-stage liver cancer in recent years. It can transform large liver cancer that cannot be removed into smaller liver cancer that can be removed. There are many methods. Generally, it is based on the dual method of hepatic artery ligation plus hepatic artery catheterization chemotherapy, plus external radiation therapy for triple therapy, and combined with immunotherapy for quadruple therapy. The effect is best with triple therapy or above. The tumor reduction rate of patients treated with multimodal comprehensive treatment reached 31%. Because the tumor was significantly reduced, they had the opportunity for second-step resection, and the second-step resection rate reached 38.1%.

Hepatic arterial chemoembolization

1. Indications

(1) The tumor is extensive, too large, or too close to the liver hilum to be resectable or not suitable for resection.

(2) Preoperative treatment of primary liver cancer can shrink the tumor, reduce intraoperative bleeding, and potentially increase the cure rate and reduce the postoperative recurrence rate.

(3) Used to eliminate residual cancer and prevent recurrence after liver resection.

(4) Liver cancer patients who are eligible for surgical resection but do not have the conditions for surgery.

(5) Patients whose liver cancer is not completely removed or whose other treatments are ineffective.

(6) Patients with ruptured and bleeding primary liver cancer nodules.

(7) For patients whose liver cancer occupies less than 70% of the liver volume, who have no cancer thrombus in the portal vein and no extrahepatic metastasis, or whose tumor occupies more than 70% of the liver volume or who have cancer thrombus in the portal vein, arterial embolization is not recommended, but arterial perfusion can still be considered.

2. Taboo

(1) Severe arteriosclerosis and abdominal aortic aneurysm.

(2) Severe portal hypertension or main trunk obstruction, active ulcer.

(3) Severe liver and kidney dysfunction, cirrhosis, severe jaundice, ascites

(4) Poor bone marrow blood function.

(5) Full or terminal stage.